Vaccine

Details Vaccine Vaccine

2003-11-03

2010-02-02

Nickol, Gary B (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Reexamination Certificate

active

07655235

ABSTRACT:
The invention relates to polynucleotides for DNA vaccination which polynucleotides encode an HIV envelope protein or fragment or immunogenic derivative, which is non-glycosylated when expressed in a mammalian target cell, operably linked to a heterologous promoter. Preferably the HIV envelope molecule, such as gp120 or gp140 or gp160, lacks a functional secretion signal. It may be fused to additional HIV proteins such as Nef, Gag, RT or Tat.

REFERENCES:
patent: 2003/0108562 (2003-06-01), Hanke et al.
patent: 2003/0190308 (2003-10-01), Braun et al.
patent: 2004/0073008 (2004-04-01), Inglesias et al.
patent: 2 430 702 (2002-09-01), None
patent: 0 577 894 (1994-01-01), None
patent: 1015596 (2006-08-01), None
patent: WO 98/41536 (1998-09-01), None
patent: WO 9841536 (1998-09-01), None
patent: 99/016884 (1999-04-01), None
patent: WO 01/27291 (2001-04-01), None
patent: 02/0220080 (2002-03-01), None
patent: WO 02/32943 (2002-04-01), None
patent: WO 02/36792 (2002-05-01), None
patent: 02/099101 (2002-12-01), None
patent: WO 03/025003 (2003-03-01), None
patent: 04/041851 (2004-05-01), None
patent: WO 2004/041852 (2004-05-01), None
Farina, S., et al., Replication-defective vector based on a chimpanzee adenovirus, Journal of Virology, 75(3):11603-11613, 2001.
Roy, S. et al., Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors, Human Gene Therapy, 15:519-530, 2004.
Fynan, E. et al., DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations, Proc. Natl. Acad. Sci. USA, 90: 11478-82, 1993.
Botarelli et al., N-Glycosylation of HIV-gpl20 May Constrain Recognition by T Lymphocytes, Journal of Immunology, 1991, 147(9):3128-3132.
Jiang et al., Construction of engineering yeast strain expressing gap-gp120 chimeric gene of HIV-1 and optimization of the expression condition, Chinese Journal of Microbiology and Immunology, 2002, 22(5):482-484. (Abstract Only).
Li et al., Glycosylation Is Necessary for the Correct Folding of Human Immunodeficiency Virus gpl20 in CD4 Binding, Journal of Virology, 1993, 67(1):584-588.
Fenouillet et al.,Virology, vol. 218 pp. 224-231 (1996).
Kayman et al.,Journal of Virology, The American Society for Microbiology, vol. 6(1) pp. 400-410 (1994).
Andre, et al.,Journal of Virology, 72(2):1497-1503 (1998).
Benko, et al.,Journal of Virology, 64(6):2505-2518 (1990).
Buck, et al,Journal of Virology, 75(1):181-191 (2001).
Doe,Eur. J. Immunol, 24:2369-75, (1994).
Hone, et al,Dev. Biol. Stand., 82:159-62, (1994).
Inglesias, et al.,J. Biochem. Mol Bio&Biophys, 5:109-122, (2000).
Kong, et al.,Journal of Virology, 77:12764-12772 (2003).
Kotsopoulou, et al.,Journal of Virology, 74(10):4839-4852 (2000).
Liu, et al.,Virology, 274(2):374-382 (2000).
Mooij, et al,Journal of Virology, 78(7):333-42 (2004).
Mooji, et al.,Vaccine, 20:304-321 (2001).
Moore, et al.,Vaccine, 17:2517-2527 (1999).
Salfeld, et al.,Embo. Journal, 9(3):965-970 (1990).
Vazquez-Blomquist, et al.,Vaccine, 22:145-155 (2003).
Woodberry, et al.,Journal of Virology, 73(7):5320-5325 (1999).
Asjo et al., Phase 1 trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy, AIDS Res Hum Retroviruses 18(18):1357-1365 (Dec 2002).
Azad et al., Large-scale production and characterization of recombinant HIV-1 Nef, J. General Virology, 75:651-655 (1994).
Berzofsky, Progress toward an artivicial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization, Biotechnol. Ther. 2(1-2): 123-135 (1991).
Betts et al., Optimal antigens for HIV vaccines based on CD8 + T response, protein length, and sequence variability, DNA Cell Biology 21(9):665-670 (Sep. 2002).
Cosma et al., Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals, Vaccine 22(1), 21-29 (Dec 2003).
Deml et al, Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein, J. Virology 75(22);10991-11001 (2001).
Estaquier et al., Comprehensive delineation of antigenic and immunogenic properties of peptides derived from the nef HIV-1 regulatory protein, Vaccine 11(11):1083-1092 (1993).
Gahery-Segard et al., Long term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+T cell epitopes recognized, J. Virol. 77(20):11220-11231 (Oct. 2003).
Gahery-Segard et al., Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine, J. Virol. 74(4):1694-1703 (Feb. 2000).
Hinkula et al., Recognition of prominent viral epitopes induced by immunization with HIV-1 regulatory genes, J. Virology, 71(7), 5528-5539 (1997).
Johnson and Walker, Cytotoxic T lymphocytes in human immunodeficiency virus infection: responses to structural protein, Curr Top Microbiol Immunol 189:35-63 (1994).
Kmieciak et al., Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by G/P-92 fusion protein expressing highly immunogenic Gag P1 7/p24 and Pol p51 antigens, J Human Virology 4(6):306-316 (2001).
Letvin et al., Progress in the development of Nan HIV-1 Vaccine, Science 280:1875 (1998).
Pialoux et al., Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers, AIDS 15(10):1239-1249 (Jul. 2001).
Robert Guroff, HIV Regulatory and accessory proteins, new targets for vaccine development, DNA and Cell Biology, 21(9): 597-598 (Sep 2002).
Zur Megede et al., Increased expression and immunogenicity of sequence modified HIV-1 gag gene, J. Virology 74:2628 (2000).

Affiliated with

Also associated with

Rating

Vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4184167